CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Autoimmune Diseases
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology), Tianjin, 300020, Tianjin, Tianjin Municipality, China
Study leads
wang ying
Principal Investigator
wangying1@ihcams.ac.cn